BioLine RX Ltd
BLRX
View Detailed Chart
3.730USD
+0.060+1.57%
Close 10/17, 16:00（ET）Quotes delayed by 15 min
9.54BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+1.57%
5 Days
-4.60%
1 Month
-3.62%
6 Months
+29.51%
Year to Date
-56.43%
1 Year
-80.16%
View Detailed Chart
TradingKey Stock Score of BioLine RX Ltd
Currency: USD Updated: 2025-10-17Key Insights
The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioLine RX Ltd's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
26.000
Target Price
+597.05%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioLine RX Ltd Highlights
StrengthsRisks
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Growing
The company is in a growing phase, with the latest annual income totaling USD 28.94M.
Overvalued
The company’s latest PE is -0.89, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 66.21K shares, decreasing 43.59% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
BioLine RX Ltd Info
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
Ticker SymbolBLRX
CompanyBioLine RX Ltd
CEOMr. Philip Adam (Phil) Serlin
Websitehttps://www.biolinerx.com/
Related Instruments
+0.76%
-6.83%
+1.57%
-0.58%
-0.50%
+0.06%
-4.46%
-3.56%
+1.32%
-1.80%
+1.68%
+0.03%
-0.10%
+0.10%
+0.31%
+8.90%
-0.73%
+0.42%
+1.95%
-3.01%Popular Symbols
